Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma.
Schmithals C, Köberle V, Korkusuz H, Pleli T, Kakoschky B, Augusto EA, Ibrahim AA, Arencibia JM, Vafaizadeh V, Groner B, Korf HW, Kronenberger B, Zeuzem S, Vogl TJ, Waidmann O, Piiper A.
Schmithals C, et al. Among authors: korf hw.
Cancer Res. 2015 Aug 1;75(15):3147-54. doi: 10.1158/0008-5472.CAN-15-0395.
Cancer Res. 2015.
PMID: 26239478